EICHORCondition: Neuroendocrine Tumors · Sponsor: ITM Solucin GmbH
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Banner Health d.b.a. Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | — |
| Stanford University | Stanford, California, United States | — |
| Moffitt Cancer Center & Research Institute | Tampa, Florida, United States | — |
| Northwestern Memorial Hospital | Chicago, Illinois, United States | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor, Michigan, United States | — |
| Excel Diagnostics & Nuclear Oncology Center | Houston, Texas, United States | — |
| Royal North Shore Hospital | Saint Leonards, New South Wales, Australia | — |
| Olivia Newton-John Cancer & Wellness Centre, Austin Hospital | Heidelberg, Victoria, Australia | — |
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | — |
| Fiona Stanley Hospital | Murdoch, Western Australia, Australia | — |
| Allgemeines Krankenhaus Wien | Vienna, Austria | — |
| Institut Jules Bordet | Brussels, Belgium | — |
+ 40 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03049189